Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Dr. Reddy's Laboratories Ltd. (NYSE:RDY) resulting from allegations that Dr. Reddy's may have issued materially misleading business information to the investing public.

On November 6, 2015, Dr. Reddy's announced that it had received a warning letter issued by the U.S. Food and Drug Administration concerning inadequate quality control standards at three of Dr. Reddy's manufacturing plants in India. On this news, shares of Dr. Reddy's fell $11.75 per share or 18.01% to close at $53.50 on November 6, 2015. Then, on August 10, 2017, Dr. Reddy's disclosed that the Regulatory of Germany (Regierung von Oberbayern), following a recent inspection of the plant, did not renew the good manufacturing practices compliance certificate of a manufacturing unit of Dr. Reddy's German subsidiary Betapharm Arzneimittel, located in Hyderabad, India. On this news, shares of Dr. Reddy's fell sharply during intraday trading on August 10, 2017, damaging investors.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Dr. Reddy's investors. If you purchased shares of Dr. Reddy's, please visit the firm's website at for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at or

Follow us for updates on LinkedIn: or on Twitter:

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on

Copyright Business Wire 2010